44TiP ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo + paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer

N. Colombo,R.L. Coleman,X. Wu,F. Kose, R. Wenham, A. Sebastianelli, K. Hasegawa, E. Zsiros,T. De La Motte Rouge,M. Bidzinski,I. McNeish,J. Sehouli, J. Korach, P.R. Debruyne,J-W. Kim,A.C. De Melo, X. Peng, A.M. Bogusz, K. Yamada,B.J. Monk

Annals of Oncology(2022)

引用 0|浏览4
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要